Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Parkinsonian Disorders | 24 | 2023 | 217 | 10.610 |
Why?
|
Aging | 91 | 2023 | 1593 | 10.190 |
Why?
|
Brain | 59 | 2023 | 1689 | 7.370 |
Why?
|
Alzheimer Disease | 69 | 2023 | 1942 | 6.810 |
Why?
|
Motor Activity | 29 | 2021 | 369 | 6.770 |
Why?
|
Aged, 80 and over | 178 | 2023 | 4851 | 6.620 |
Why?
|
Cognitive Dysfunction | 35 | 2023 | 938 | 5.850 |
Why?
|
Cognition | 46 | 2023 | 1277 | 5.660 |
Why?
|
Aged | 185 | 2023 | 9448 | 5.330 |
Why?
|
Disabled Persons | 16 | 2023 | 127 | 5.150 |
Why?
|
Male | 199 | 2023 | 15621 | 4.440 |
Why?
|
Female | 195 | 2023 | 16197 | 4.200 |
Why?
|
Parkinson Disease | 26 | 2023 | 1164 | 4.200 |
Why?
|
Humans | 252 | 2023 | 29337 | 4.010 |
Why?
|
Independent Living | 16 | 2023 | 281 | 3.720 |
Why?
|
Mobility Limitation | 11 | 2021 | 97 | 3.620 |
Why?
|
Exercise | 15 | 2023 | 468 | 3.560 |
Why?
|
Cognition Disorders | 39 | 2021 | 1011 | 3.460 |
Why?
|
Dementia | 23 | 2023 | 521 | 3.200 |
Why?
|
Longitudinal Studies | 56 | 2023 | 1442 | 3.010 |
Why?
|
Intracranial Arteriosclerosis | 5 | 2022 | 51 | 3.000 |
Why?
|
Gait | 14 | 2023 | 404 | 2.930 |
Why?
|
Activities of Daily Living | 27 | 2023 | 501 | 2.880 |
Why?
|
Arteriolosclerosis | 7 | 2023 | 71 | 2.830 |
Why?
|
Geriatric Assessment | 17 | 2021 | 219 | 2.770 |
Why?
|
Frail Elderly | 8 | 2021 | 51 | 2.620 |
Why?
|
Muscle Strength | 15 | 2021 | 127 | 2.610 |
Why?
|
Cohort Studies | 59 | 2021 | 1939 | 2.400 |
Why?
|
Cerebrovascular Disorders | 6 | 2023 | 132 | 2.390 |
Why?
|
Spinal Cord | 5 | 2022 | 103 | 2.150 |
Why?
|
Residence Characteristics | 13 | 2021 | 216 | 2.050 |
Why?
|
Risk Factors | 46 | 2023 | 2443 | 2.040 |
Why?
|
Wearable Electronic Devices | 6 | 2021 | 40 | 1.980 |
Why?
|
Proportional Hazards Models | 24 | 2021 | 340 | 1.910 |
Why?
|
Motor Skills | 6 | 2021 | 61 | 1.880 |
Why?
|
Disability Evaluation | 18 | 2020 | 327 | 1.850 |
Why?
|
Hand Strength | 7 | 2023 | 59 | 1.760 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 63 | 1.750 |
Why?
|
Brain Diseases | 4 | 2020 | 82 | 1.750 |
Why?
|
Disease Progression | 19 | 2021 | 787 | 1.740 |
Why?
|
Neuropsychological Tests | 37 | 2023 | 1251 | 1.740 |
Why?
|
Sarcopenia | 3 | 2021 | 26 | 1.740 |
Why?
|
Memory | 15 | 2019 | 318 | 1.690 |
Why?
|
Motor Disorders | 4 | 2023 | 22 | 1.670 |
Why?
|
Walking Speed | 3 | 2021 | 41 | 1.640 |
Why?
|
Follow-Up Studies | 26 | 2021 | 1830 | 1.590 |
Why?
|
Cerebral Amyloid Angiopathy | 5 | 2021 | 115 | 1.560 |
Why?
|
Genetic Predisposition to Disease | 15 | 2021 | 441 | 1.530 |
Why?
|
Lewy Body Disease | 7 | 2021 | 98 | 1.510 |
Why?
|
White Matter | 5 | 2021 | 149 | 1.470 |
Why?
|
Psychomotor Performance | 7 | 2021 | 216 | 1.450 |
Why?
|
Sleep Deprivation | 6 | 2022 | 63 | 1.440 |
Why?
|
Prospective Studies | 26 | 2023 | 1811 | 1.400 |
Why?
|
Autopsy | 16 | 2022 | 335 | 1.390 |
Why?
|
Frailty | 4 | 2023 | 38 | 1.360 |
Why?
|
Neurons | 10 | 2022 | 374 | 1.350 |
Why?
|
Movement Disorders | 5 | 2021 | 141 | 1.300 |
Why?
|
Postural Balance | 7 | 2021 | 121 | 1.300 |
Why?
|
Muscle Weakness | 5 | 2021 | 32 | 1.250 |
Why?
|
Lewy Bodies | 15 | 2023 | 195 | 1.240 |
Why?
|
Incidence | 15 | 2021 | 756 | 1.230 |
Why?
|
Movement | 4 | 2020 | 143 | 1.180 |
Why?
|
Nervous System Diseases | 4 | 2017 | 145 | 1.150 |
Why?
|
Urinary Incontinence | 2 | 2017 | 24 | 1.140 |
Why?
|
Muscle, Skeletal | 8 | 2021 | 349 | 1.130 |
Why?
|
Accelerometry | 5 | 2021 | 87 | 1.100 |
Why?
|
Amyloid beta-Peptides | 8 | 2023 | 294 | 1.040 |
Why?
|
Genome-Wide Association Study | 15 | 2021 | 301 | 1.030 |
Why?
|
Cerebral Infarction | 6 | 2016 | 152 | 1.030 |
Why?
|
Atherosclerosis | 2 | 2023 | 72 | 1.020 |
Why?
|
Walking | 9 | 2023 | 252 | 1.020 |
Why?
|
Prefrontal Cortex | 5 | 2023 | 152 | 1.020 |
Why?
|
Memory, Episodic | 5 | 2023 | 116 | 1.010 |
Why?
|
Cerebral Cortex | 4 | 2021 | 195 | 0.980 |
Why?
|
Apolipoprotein E4 | 9 | 2020 | 227 | 0.980 |
Why?
|
Actigraphy | 17 | 2022 | 98 | 0.970 |
Why?
|
Age Factors | 20 | 2021 | 843 | 0.970 |
Why?
|
Neuropeptides | 1 | 2023 | 29 | 0.960 |
Why?
|
Resilience, Psychological | 1 | 2023 | 24 | 0.940 |
Why?
|
Cognitive Aging | 2 | 2021 | 81 | 0.930 |
Why?
|
TDP-43 Proteinopathies | 2 | 2023 | 104 | 0.910 |
Why?
|
Glycation End Products, Advanced | 2 | 2022 | 7 | 0.910 |
Why?
|
Body Mass Index | 7 | 2023 | 428 | 0.900 |
Why?
|
Cerebrum | 1 | 2023 | 9 | 0.900 |
Why?
|
Substantia Nigra | 5 | 2021 | 148 | 0.900 |
Why?
|
Sleep | 12 | 2022 | 313 | 0.860 |
Why?
|
Brain Infarction | 6 | 2020 | 74 | 0.770 |
Why?
|
Motor Neurons | 3 | 2018 | 21 | 0.770 |
Why?
|
Middle Aged | 48 | 2021 | 9823 | 0.770 |
Why?
|
Peptides | 1 | 2021 | 95 | 0.760 |
Why?
|
Mortality | 4 | 2020 | 86 | 0.740 |
Why?
|
Brain-Derived Neurotrophic Factor | 2 | 2021 | 39 | 0.740 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 2 | 2019 | 27 | 0.740 |
Why?
|
Magnetic Resonance Imaging | 12 | 2021 | 1221 | 0.730 |
Why?
|
Chicago | 14 | 2021 | 865 | 0.730 |
Why?
|
Longevity | 4 | 2014 | 32 | 0.730 |
Why?
|
Gait Disorders, Neurologic | 7 | 2021 | 144 | 0.720 |
Why?
|
Polymorphism, Single Nucleotide | 12 | 2021 | 306 | 0.700 |
Why?
|
Range of Motion, Articular | 2 | 2019 | 699 | 0.700 |
Why?
|
Lung | 3 | 2021 | 154 | 0.690 |
Why?
|
Linear Models | 9 | 2023 | 254 | 0.690 |
Why?
|
Circadian Rhythm | 7 | 2023 | 280 | 0.690 |
Why?
|
Apolipoproteins E | 4 | 2018 | 230 | 0.670 |
Why?
|
Executive Function | 3 | 2022 | 121 | 0.660 |
Why?
|
Microvessels | 1 | 2017 | 16 | 0.620 |
Why?
|
Olfaction Disorders | 5 | 2021 | 53 | 0.620 |
Why?
|
Proteome | 3 | 2023 | 39 | 0.620 |
Why?
|
Phenotype | 9 | 2023 | 355 | 0.600 |
Why?
|
Locus Coeruleus | 3 | 2013 | 23 | 0.590 |
Why?
|
Proteomics | 3 | 2023 | 91 | 0.590 |
Why?
|
United States | 13 | 2021 | 2333 | 0.570 |
Why?
|
Time Factors | 14 | 2021 | 1616 | 0.570 |
Why?
|
Regression Analysis | 6 | 2020 | 298 | 0.570 |
Why?
|
alpha-Synuclein | 4 | 2018 | 138 | 0.560 |
Why?
|
tau Proteins | 5 | 2023 | 202 | 0.560 |
Why?
|
Sex Factors | 10 | 2020 | 496 | 0.560 |
Why?
|
Motor Skills Disorders | 2 | 2018 | 18 | 0.550 |
Why?
|
Electromyography | 6 | 2001 | 78 | 0.550 |
Why?
|
Body Composition | 3 | 2019 | 56 | 0.540 |
Why?
|
Visceral Afferents | 1 | 2015 | 4 | 0.540 |
Why?
|
Spinal Cord Dorsal Horn | 1 | 2015 | 8 | 0.540 |
Why?
|
Comorbidity | 6 | 2021 | 498 | 0.530 |
Why?
|
Genotype | 10 | 2018 | 405 | 0.520 |
Why?
|
Sleep Wake Disorders | 5 | 2019 | 148 | 0.520 |
Why?
|
Multiple System Atrophy | 1 | 2015 | 42 | 0.510 |
Why?
|
Self Report | 5 | 2021 | 218 | 0.510 |
Why?
|
Harm Reduction | 1 | 2014 | 5 | 0.500 |
Why?
|
Locomotion | 1 | 2014 | 24 | 0.480 |
Why?
|
Severity of Illness Index | 10 | 2021 | 1113 | 0.470 |
Why?
|
Neuroimaging | 3 | 2021 | 136 | 0.470 |
Why?
|
Vascular Diseases | 2 | 2013 | 48 | 0.470 |
Why?
|
Musculoskeletal Diseases | 2 | 2010 | 41 | 0.460 |
Why?
|
Psychomotor Disorders | 1 | 2013 | 10 | 0.460 |
Why?
|
Physical Fitness | 3 | 2009 | 59 | 0.460 |
Why?
|
Logistic Models | 8 | 2020 | 407 | 0.450 |
Why?
|
Consensus | 1 | 2013 | 105 | 0.450 |
Why?
|
DNA Methylation | 3 | 2021 | 124 | 0.450 |
Why?
|
Cardiovascular Diseases | 4 | 2022 | 402 | 0.450 |
Why?
|
Neurodegenerative Diseases | 3 | 2021 | 117 | 0.450 |
Why?
|
Knee Joint | 1 | 2019 | 797 | 0.450 |
Why?
|
Quantitative Trait Loci | 5 | 2020 | 61 | 0.440 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 200 | 0.430 |
Why?
|
Hippocampus | 4 | 2019 | 274 | 0.430 |
Why?
|
Kidney | 3 | 2010 | 173 | 0.430 |
Why?
|
Gene Expression | 5 | 2020 | 226 | 0.430 |
Why?
|
C-Reactive Protein | 1 | 2012 | 125 | 0.420 |
Why?
|
Survival Rate | 2 | 2012 | 349 | 0.420 |
Why?
|
Respiratory Muscles | 2 | 2008 | 18 | 0.420 |
Why?
|
Sex Characteristics | 4 | 2018 | 132 | 0.410 |
Why?
|
Fatigue | 2 | 2009 | 59 | 0.410 |
Why?
|
Anxiety Disorders | 1 | 2013 | 168 | 0.410 |
Why?
|
Olfactory Bulb | 2 | 2023 | 16 | 0.410 |
Why?
|
Leg | 3 | 2008 | 49 | 0.410 |
Why?
|
Loneliness | 2 | 2014 | 52 | 0.400 |
Why?
|
Myasthenia Gravis | 2 | 2006 | 11 | 0.400 |
Why?
|
Microglia | 3 | 2021 | 124 | 0.390 |
Why?
|
Neurofibrillary Tangles | 4 | 2023 | 181 | 0.390 |
Why?
|
DNA-Binding Proteins | 5 | 2023 | 254 | 0.390 |
Why?
|
Risk Assessment | 7 | 2021 | 679 | 0.380 |
Why?
|
Pain | 2 | 2010 | 391 | 0.370 |
Why?
|
Illinois | 4 | 2020 | 241 | 0.370 |
Why?
|
Educational Status | 6 | 2015 | 295 | 0.360 |
Why?
|
Diet | 2 | 2022 | 174 | 0.360 |
Why?
|
Psychiatric Status Rating Scales | 5 | 2015 | 343 | 0.360 |
Why?
|
Somatosensory Disorders | 1 | 2009 | 10 | 0.350 |
Why?
|
Sensory Thresholds | 1 | 2009 | 24 | 0.350 |
Why?
|
Social Adjustment | 1 | 2009 | 28 | 0.350 |
Why?
|
Vibration | 1 | 2009 | 26 | 0.350 |
Why?
|
Polyneuropathies | 1 | 2008 | 3 | 0.340 |
Why?
|
Neocortex | 3 | 2019 | 34 | 0.340 |
Why?
|
Peripheral Nerves | 1 | 2008 | 20 | 0.340 |
Why?
|
Health Status | 2 | 2012 | 227 | 0.340 |
Why?
|
Genome, Human | 2 | 2020 | 49 | 0.330 |
Why?
|
Isometric Contraction | 3 | 2007 | 15 | 0.330 |
Why?
|
ROC Curve | 3 | 2022 | 138 | 0.320 |
Why?
|
Rest | 4 | 2023 | 32 | 0.320 |
Why?
|
Cross-Sectional Studies | 10 | 2021 | 959 | 0.320 |
Why?
|
Diet, Mediterranean | 2 | 2019 | 62 | 0.320 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2009 | 97 | 0.310 |
Why?
|
Risk | 9 | 2020 | 217 | 0.310 |
Why?
|
Synapses | 2 | 2021 | 50 | 0.310 |
Why?
|
Causality | 2 | 2021 | 53 | 0.310 |
Why?
|
Tremor | 3 | 2021 | 141 | 0.300 |
Why?
|
Models, Statistical | 2 | 2020 | 132 | 0.290 |
Why?
|
Thymoma | 1 | 2006 | 13 | 0.290 |
Why?
|
Thymus Neoplasms | 1 | 2006 | 12 | 0.290 |
Why?
|
Myositis | 1 | 2006 | 23 | 0.280 |
Why?
|
Antibodies, Antiphospholipid | 2 | 2019 | 26 | 0.280 |
Why?
|
Eosinophilia | 1 | 2006 | 47 | 0.280 |
Why?
|
Life Style | 3 | 2020 | 211 | 0.280 |
Why?
|
Adult | 21 | 2019 | 8601 | 0.280 |
Why?
|
Exercise Therapy | 1 | 2007 | 112 | 0.280 |
Why?
|
Dystonia | 2 | 1998 | 53 | 0.270 |
Why?
|
Cachexia | 1 | 2005 | 11 | 0.270 |
Why?
|
Goals | 3 | 2010 | 43 | 0.270 |
Why?
|
Alleles | 7 | 2018 | 224 | 0.260 |
Why?
|
Memory Disorders | 5 | 2015 | 174 | 0.260 |
Why?
|
Postmortem Changes | 2 | 2016 | 34 | 0.250 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 521 | 0.250 |
Why?
|
Electric Impedance | 2 | 2021 | 24 | 0.250 |
Why?
|
Self-Assessment | 2 | 2021 | 29 | 0.250 |
Why?
|
GPI-Linked Proteins | 1 | 2023 | 25 | 0.240 |
Why?
|
Diagnostic Techniques, Neurological | 2 | 2021 | 10 | 0.240 |
Why?
|
Analysis of Variance | 3 | 2021 | 321 | 0.240 |
Why?
|
RNA, Messenger | 4 | 2017 | 323 | 0.240 |
Why?
|
Physical Therapy Modalities | 2 | 2022 | 80 | 0.240 |
Why?
|
Transcriptome | 2 | 2021 | 83 | 0.240 |
Why?
|
Limbic Encephalitis | 1 | 2023 | 10 | 0.230 |
Why?
|
Adaptor Protein Complex 1 | 1 | 2023 | 5 | 0.230 |
Why?
|
Adaptor Protein Complex beta Subunits | 1 | 2023 | 5 | 0.230 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 74 | 0.230 |
Why?
|
Fitness Trackers | 2 | 2021 | 13 | 0.230 |
Why?
|
Genetic Association Studies | 4 | 2016 | 86 | 0.220 |
Why?
|
Animals | 7 | 2022 | 4552 | 0.220 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 153 | 0.220 |
Why?
|
Triglycerides | 1 | 2022 | 41 | 0.220 |
Why?
|
Gene Expression Regulation | 4 | 2021 | 284 | 0.220 |
Why?
|
Glycopeptides | 1 | 2022 | 4 | 0.220 |
Why?
|
Cholesterol | 1 | 2022 | 50 | 0.220 |
Why?
|
Sequence Analysis, RNA | 5 | 2023 | 42 | 0.220 |
Why?
|
Decision Making | 3 | 2013 | 220 | 0.210 |
Why?
|
Individuality | 1 | 2022 | 22 | 0.210 |
Why?
|
Interpersonal Relations | 2 | 2014 | 105 | 0.210 |
Why?
|
Cognitive Reserve | 1 | 2022 | 37 | 0.210 |
Why?
|
Prognosis | 4 | 2019 | 840 | 0.210 |
Why?
|
Eating | 1 | 2022 | 45 | 0.210 |
Why?
|
Blood Pressure | 2 | 2020 | 238 | 0.210 |
Why?
|
Reaction Time | 3 | 2016 | 123 | 0.210 |
Why?
|
Cell Count | 4 | 2015 | 99 | 0.200 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 125 | 0.200 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2021 | 12 | 0.200 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2021 | 6 | 0.200 |
Why?
|
Lumbar Vertebrae | 2 | 2018 | 487 | 0.200 |
Why?
|
Proteins | 2 | 2020 | 72 | 0.200 |
Why?
|
Genetic Variation | 3 | 2016 | 105 | 0.200 |
Why?
|
Amygdala | 1 | 2021 | 50 | 0.200 |
Why?
|
Apolipoprotein C-I | 1 | 2020 | 2 | 0.200 |
Why?
|
Ribonucleases | 1 | 2020 | 9 | 0.200 |
Why?
|
Membrane Transport Proteins | 1 | 2021 | 50 | 0.190 |
Why?
|
Chronobiology Disorders | 1 | 2020 | 14 | 0.190 |
Why?
|
Sex Distribution | 2 | 2012 | 87 | 0.190 |
Why?
|
Carrier Proteins | 1 | 2021 | 97 | 0.190 |
Why?
|
Membrane Glycoproteins | 1 | 2021 | 101 | 0.190 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2020 | 38 | 0.190 |
Why?
|
Reference Values | 3 | 2012 | 227 | 0.190 |
Why?
|
Nerve Tissue Proteins | 3 | 2021 | 173 | 0.190 |
Why?
|
Antioxidants | 1 | 2020 | 56 | 0.180 |
Why?
|
Personality | 2 | 2013 | 68 | 0.180 |
Why?
|
Hypertension | 3 | 2020 | 266 | 0.180 |
Why?
|
Multifactorial Inheritance | 1 | 2019 | 24 | 0.180 |
Why?
|
Torticollis | 2 | 1998 | 69 | 0.180 |
Why?
|
Histones | 1 | 2019 | 28 | 0.180 |
Why?
|
Infarction | 2 | 2023 | 23 | 0.180 |
Why?
|
Dietary Approaches To Stop Hypertension | 1 | 2019 | 20 | 0.170 |
Why?
|
Body Fluid Compartments | 1 | 2019 | 4 | 0.170 |
Why?
|
Risk-Taking | 2 | 2011 | 32 | 0.170 |
Why?
|
Neuropathology | 2 | 2019 | 79 | 0.170 |
Why?
|
Temporal Lobe | 2 | 2017 | 105 | 0.170 |
Why?
|
Social Environment | 2 | 2011 | 79 | 0.170 |
Why?
|
Cause of Death | 2 | 2009 | 65 | 0.170 |
Why?
|
Suprachiasmatic Nucleus | 2 | 2015 | 15 | 0.170 |
Why?
|
Seasons | 1 | 2018 | 31 | 0.170 |
Why?
|
Heart Failure | 1 | 2021 | 202 | 0.160 |
Why?
|
Head Movements | 1 | 1998 | 7 | 0.160 |
Why?
|
Neck Muscles | 1 | 1998 | 13 | 0.160 |
Why?
|
Adipose Tissue | 1 | 2019 | 73 | 0.160 |
Why?
|
Odds Ratio | 2 | 2016 | 285 | 0.160 |
Why?
|
Prodromal Symptoms | 1 | 2018 | 19 | 0.160 |
Why?
|
Haptoglobins | 1 | 2017 | 5 | 0.160 |
Why?
|
Pseudogenes | 1 | 2017 | 2 | 0.160 |
Why?
|
Young Adult | 5 | 2019 | 1932 | 0.160 |
Why?
|
Thinness | 1 | 2017 | 4 | 0.160 |
Why?
|
Depression | 4 | 2016 | 465 | 0.160 |
Why?
|
Anterior Horn Cells | 1 | 2017 | 1 | 0.160 |
Why?
|
Hypokinesia | 3 | 2014 | 27 | 0.160 |
Why?
|
Lipid Metabolism | 1 | 2017 | 31 | 0.150 |
Why?
|
Corpus Striatum | 1 | 2018 | 111 | 0.150 |
Why?
|
RNA | 1 | 2017 | 39 | 0.150 |
Why?
|
Quality of Life | 3 | 2012 | 662 | 0.150 |
Why?
|
Immunohistochemistry | 2 | 2015 | 391 | 0.150 |
Why?
|
MicroRNAs | 1 | 2017 | 42 | 0.150 |
Why?
|
Energy Metabolism | 2 | 2019 | 52 | 0.150 |
Why?
|
Blood Glucose | 1 | 2017 | 112 | 0.150 |
Why?
|
Lumbosacral Region | 1 | 2017 | 69 | 0.140 |
Why?
|
Memory, Short-Term | 4 | 2021 | 102 | 0.140 |
Why?
|
Task Performance and Analysis | 1 | 2016 | 55 | 0.140 |
Why?
|
Early Diagnosis | 2 | 2014 | 65 | 0.140 |
Why?
|
Haplotypes | 1 | 2016 | 61 | 0.140 |
Why?
|
Botulinum Toxins | 2 | 1993 | 32 | 0.140 |
Why?
|
Muscle Rigidity | 2 | 2014 | 26 | 0.140 |
Why?
|
Cerebral Arteries | 1 | 2016 | 30 | 0.140 |
Why?
|
Data Interpretation, Statistical | 3 | 2014 | 96 | 0.140 |
Why?
|
Homes for the Aged | 1 | 2015 | 9 | 0.140 |
Why?
|
Period Circadian Proteins | 2 | 2013 | 23 | 0.140 |
Why?
|
Intention | 3 | 2010 | 26 | 0.140 |
Why?
|
Body Size | 1 | 2015 | 11 | 0.140 |
Why?
|
Receptors, Complement 3b | 2 | 2016 | 15 | 0.140 |
Why?
|
Receptors, Dopamine D2 | 1 | 2015 | 18 | 0.140 |
Why?
|
Case-Control Studies | 5 | 2020 | 638 | 0.140 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2015 | 3 | 0.140 |
Why?
|
Adiposity | 1 | 2016 | 47 | 0.140 |
Why?
|
Gray Matter | 1 | 2016 | 56 | 0.130 |
Why?
|
Sacrum | 1 | 2015 | 27 | 0.130 |
Why?
|
Fractals | 3 | 2019 | 22 | 0.130 |
Why?
|
Healthy Volunteers | 1 | 2015 | 46 | 0.130 |
Why?
|
Heart Diseases | 1 | 2016 | 73 | 0.130 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 85 | 0.130 |
Why?
|
Preoptic Area | 1 | 2014 | 6 | 0.130 |
Why?
|
Biomarkers | 4 | 2021 | 689 | 0.130 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 20 | 0.130 |
Why?
|
Sensation Disorders | 1 | 2014 | 13 | 0.130 |
Why?
|
Transcription, Genetic | 1 | 2014 | 108 | 0.130 |
Why?
|
Retirement | 2 | 2011 | 11 | 0.130 |
Why?
|
Metabolic Syndrome | 1 | 2015 | 66 | 0.130 |
Why?
|
Disease Models, Animal | 1 | 2017 | 724 | 0.120 |
Why?
|
HIV Infections | 1 | 2021 | 970 | 0.120 |
Why?
|
Genetic Loci | 1 | 2014 | 61 | 0.120 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 111 | 0.120 |
Why?
|
Stress, Psychological | 2 | 2014 | 246 | 0.120 |
Why?
|
Mesencephalon | 1 | 2013 | 44 | 0.120 |
Why?
|
Telemetry | 1 | 2013 | 11 | 0.120 |
Why?
|
Dyssomnias | 1 | 2013 | 8 | 0.120 |
Why?
|
Financial Management | 1 | 2013 | 24 | 0.120 |
Why?
|
Synucleins | 1 | 2013 | 7 | 0.110 |
Why?
|
Muscles | 1 | 1993 | 72 | 0.110 |
Why?
|
CLOCK Proteins | 1 | 2013 | 26 | 0.110 |
Why?
|
Brain Stem | 1 | 2013 | 25 | 0.110 |
Why?
|
Early Medical Intervention | 1 | 2013 | 14 | 0.110 |
Why?
|
Gene Frequency | 1 | 2013 | 75 | 0.110 |
Why?
|
Neuroticism | 1 | 2013 | 33 | 0.110 |
Why?
|
Health Surveys | 1 | 2013 | 96 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2012 | 16 | 0.110 |
Why?
|
Time Perception | 1 | 2012 | 6 | 0.110 |
Why?
|
Musculoskeletal Pain | 1 | 2012 | 20 | 0.110 |
Why?
|
Glucosylceramidase | 1 | 2012 | 26 | 0.110 |
Why?
|
Social Behavior | 2 | 2011 | 98 | 0.110 |
Why?
|
Amyloid | 1 | 2012 | 53 | 0.110 |
Why?
|
Neuromuscular Junction | 1 | 1992 | 7 | 0.110 |
Why?
|
Anxiety | 1 | 2013 | 152 | 0.110 |
Why?
|
Child Abuse | 1 | 2012 | 36 | 0.110 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 78 | 0.110 |
Why?
|
Atrophy | 2 | 2009 | 102 | 0.110 |
Why?
|
Confidence Intervals | 1 | 2012 | 96 | 0.110 |
Why?
|
Data Collection | 2 | 2010 | 107 | 0.110 |
Why?
|
Choice Behavior | 1 | 2012 | 56 | 0.100 |
Why?
|
Emotions | 1 | 2012 | 90 | 0.100 |
Why?
|
Health Literacy | 1 | 2013 | 102 | 0.100 |
Why?
|
Chronic Pain | 1 | 2012 | 112 | 0.100 |
Why?
|
Wakefulness | 1 | 2011 | 81 | 0.100 |
Why?
|
Urban Population | 2 | 2010 | 143 | 0.100 |
Why?
|
Algorithms | 3 | 2021 | 400 | 0.100 |
Why?
|
Social Participation | 1 | 2011 | 10 | 0.100 |
Why?
|
Environmental Health | 1 | 2010 | 8 | 0.100 |
Why?
|
Hemoglobins | 1 | 2011 | 81 | 0.100 |
Why?
|
Mutation | 1 | 2012 | 383 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 138 | 0.090 |
Why?
|
Glomerular Filtration Rate | 2 | 2009 | 59 | 0.090 |
Why?
|
Phobic Disorders | 1 | 2010 | 62 | 0.090 |
Why?
|
Plaque, Amyloid | 1 | 2011 | 144 | 0.090 |
Why?
|
Potassium | 1 | 2010 | 67 | 0.090 |
Why?
|
Image Enhancement | 1 | 1990 | 57 | 0.090 |
Why?
|
Spinal Cord Neoplasms | 1 | 1990 | 34 | 0.090 |
Why?
|
Respiratory Function Tests | 1 | 2009 | 32 | 0.090 |
Why?
|
Microcirculation | 1 | 2009 | 37 | 0.090 |
Why?
|
Mechanoreceptors | 1 | 2009 | 7 | 0.090 |
Why?
|
Proprioception | 1 | 2009 | 19 | 0.090 |
Why?
|
Neurologic Examination | 2 | 2007 | 146 | 0.090 |
Why?
|
Age Distribution | 1 | 2009 | 94 | 0.090 |
Why?
|
Sural Nerve | 1 | 2008 | 4 | 0.090 |
Why?
|
Peroneal Nerve | 1 | 2008 | 6 | 0.090 |
Why?
|
Ergometry | 1 | 2008 | 3 | 0.080 |
Why?
|
Electrophysiology | 1 | 2008 | 129 | 0.080 |
Why?
|
Foot | 1 | 2008 | 30 | 0.080 |
Why?
|
Electric Stimulation | 1 | 2008 | 83 | 0.080 |
Why?
|
Research Design | 2 | 2012 | 212 | 0.080 |
Why?
|
Joints | 1 | 2009 | 97 | 0.080 |
Why?
|
Extremities | 1 | 2008 | 31 | 0.080 |
Why?
|
ADAMTS Proteins | 2 | 2019 | 5 | 0.080 |
Why?
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2019 | 5 | 0.080 |
Why?
|
Versicans | 2 | 2019 | 15 | 0.080 |
Why?
|
Inflammation | 1 | 2010 | 344 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2021 | 173 | 0.080 |
Why?
|
Catholicism | 1 | 2007 | 21 | 0.080 |
Why?
|
Action Potentials | 1 | 2008 | 136 | 0.080 |
Why?
|
Extracellular Matrix Proteins | 2 | 2019 | 127 | 0.080 |
Why?
|
Bromocriptine | 1 | 1987 | 15 | 0.080 |
Why?
|
Myoclonus | 1 | 1987 | 29 | 0.080 |
Why?
|
Visual Perception | 1 | 2007 | 50 | 0.080 |
Why?
|
Lower Extremity | 1 | 2007 | 38 | 0.080 |
Why?
|
Retrospective Studies | 5 | 2014 | 3273 | 0.080 |
Why?
|
Dementia, Vascular | 1 | 2007 | 41 | 0.080 |
Why?
|
Personal Space | 1 | 2007 | 6 | 0.080 |
Why?
|
Alternative Splicing | 2 | 2017 | 25 | 0.080 |
Why?
|
Exercise Tolerance | 1 | 2007 | 33 | 0.070 |
Why?
|
Clergy | 1 | 2007 | 90 | 0.070 |
Why?
|
Pyridostigmine Bromide | 1 | 2006 | 2 | 0.070 |
Why?
|
Neural Conduction | 1 | 2006 | 8 | 0.070 |
Why?
|
Blood Cell Count | 1 | 2006 | 15 | 0.070 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 16 | 0.070 |
Why?
|
Eye Movements | 1 | 2006 | 20 | 0.070 |
Why?
|
Heterozygote | 2 | 2018 | 103 | 0.070 |
Why?
|
Peritonitis | 1 | 2006 | 15 | 0.070 |
Why?
|
Ophthalmoplegia | 1 | 1986 | 2 | 0.070 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 138 | 0.070 |
Why?
|
Quadriplegia | 1 | 1986 | 8 | 0.070 |
Why?
|
Prednisone | 1 | 2006 | 67 | 0.070 |
Why?
|
Diagnosis | 2 | 2016 | 23 | 0.070 |
Why?
|
Biotechnology | 1 | 2005 | 3 | 0.070 |
Why?
|
Motion Therapy, Continuous Passive | 1 | 2005 | 5 | 0.070 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 7 | 0.070 |
Why?
|
Rehabilitation | 1 | 2005 | 14 | 0.070 |
Why?
|
Robotics | 1 | 2005 | 10 | 0.070 |
Why?
|
Medical Informatics | 1 | 2005 | 9 | 0.070 |
Why?
|
Brain Mapping | 2 | 2020 | 195 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 100 | 0.070 |
Why?
|
Sialorrhea | 1 | 2005 | 5 | 0.070 |
Why?
|
Body Weight | 1 | 2005 | 133 | 0.070 |
Why?
|
Neuromuscular Agents | 1 | 2005 | 19 | 0.070 |
Why?
|
Botulinum Toxins, Type A | 1 | 2005 | 34 | 0.060 |
Why?
|
Stiff-Person Syndrome | 1 | 2004 | 1 | 0.060 |
Why?
|
West Nile Fever | 1 | 2004 | 4 | 0.060 |
Why?
|
Elbow | 2 | 2001 | 42 | 0.060 |
Why?
|
Adolescent | 3 | 2019 | 2279 | 0.060 |
Why?
|
Forced Expiratory Volume | 1 | 2022 | 8 | 0.060 |
Why?
|
Vital Capacity | 1 | 2022 | 9 | 0.060 |
Why?
|
Wrist | 1 | 2022 | 17 | 0.060 |
Why?
|
Boronic Acids | 1 | 2022 | 4 | 0.060 |
Why?
|
Glycosylation | 1 | 2022 | 24 | 0.050 |
Why?
|
Polysaccharides | 1 | 2022 | 15 | 0.050 |
Why?
|
Stem Cells | 1 | 2022 | 46 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 96 | 0.050 |
Why?
|
Machine Learning | 1 | 2022 | 54 | 0.050 |
Why?
|
Synaptophysin | 1 | 2021 | 9 | 0.050 |
Why?
|
Synaptotagmins | 1 | 2021 | 5 | 0.050 |
Why?
|
Synapsins | 1 | 2021 | 6 | 0.050 |
Why?
|
Qa-SNARE Proteins | 1 | 2021 | 7 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2021 | 21 | 0.050 |
Why?
|
Epigenomics | 1 | 2021 | 12 | 0.050 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 42 | 0.050 |
Why?
|
CpG Islands | 1 | 2021 | 34 | 0.050 |
Why?
|
Boston | 1 | 2021 | 27 | 0.050 |
Why?
|
beta-Lactamases | 1 | 2021 | 72 | 0.050 |
Why?
|
Acute-Phase Proteins | 1 | 2021 | 14 | 0.050 |
Why?
|
Astrocytes | 1 | 2022 | 122 | 0.050 |
Why?
|
HLA-DQ alpha-Chains | 1 | 2021 | 2 | 0.050 |
Why?
|
Growth Differentiation Factor 5 | 1 | 2021 | 8 | 0.050 |
Why?
|
Europe | 1 | 2021 | 81 | 0.050 |
Why?
|
HLA-DRB1 Chains | 1 | 2020 | 3 | 0.050 |
Why?
|
Israel | 1 | 2020 | 16 | 0.050 |
Why?
|
Stroke | 2 | 2016 | 293 | 0.050 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 34 | 0.050 |
Why?
|
Myosin Heavy Chains | 1 | 2020 | 6 | 0.050 |
Why?
|
Genetic Markers | 1 | 2020 | 58 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2020 | 39 | 0.050 |
Why?
|
Carotenoids | 1 | 2020 | 9 | 0.050 |
Why?
|
Memory and Learning Tests | 1 | 2020 | 7 | 0.050 |
Why?
|
Insect Proteins | 1 | 2000 | 1 | 0.050 |
Why?
|
Genes, Tumor Suppressor | 1 | 2000 | 11 | 0.050 |
Why?
|
Ascorbic Acid | 1 | 2020 | 32 | 0.050 |
Why?
|
Drosophila melanogaster | 2 | 2016 | 18 | 0.050 |
Why?
|
Vitamin E | 1 | 2020 | 27 | 0.050 |
Why?
|
Mental Status and Dementia Tests | 1 | 2020 | 80 | 0.050 |
Why?
|
Biopsy, Needle | 1 | 2020 | 101 | 0.050 |
Why?
|
Acetylation | 1 | 2019 | 13 | 0.050 |
Why?
|
Synaptic Vesicles | 1 | 2019 | 4 | 0.040 |
Why?
|
Computer Simulation | 1 | 2020 | 218 | 0.040 |
Why?
|
Microarray Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2019 | 3 | 0.040 |
Why?
|
RNA-Binding Proteins | 1 | 2019 | 22 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2000 | 89 | 0.040 |
Why?
|
Survival Analysis | 1 | 2019 | 298 | 0.040 |
Why?
|
Axons | 1 | 2019 | 38 | 0.040 |
Why?
|
Odorants | 2 | 2009 | 23 | 0.040 |
Why?
|
Time and Motion Studies | 1 | 2018 | 16 | 0.040 |
Why?
|
Neuronal Plasticity | 1 | 2019 | 43 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2019 | 76 | 0.040 |
Why?
|
Muscle Strength Dynamometer | 2 | 2009 | 15 | 0.040 |
Why?
|
Protein Interaction Maps | 1 | 2018 | 17 | 0.040 |
Why?
|
Mitochondria | 1 | 2019 | 78 | 0.040 |
Why?
|
Smoking | 1 | 2020 | 194 | 0.040 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2018 | 19 | 0.040 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 50 | 0.040 |
Why?
|
Psychometrics | 2 | 2010 | 262 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 1998 | 38 | 0.040 |
Why?
|
Religious Personnel | 1 | 2018 | 11 | 0.040 |
Why?
|
Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.040 |
Why?
|
alpha-Macroglobulins | 1 | 2017 | 12 | 0.040 |
Why?
|
Surveys and Questionnaires | 2 | 2016 | 1184 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 37 | 0.040 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2017 | 2 | 0.040 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2017 | 2 | 0.040 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 5 | 0.040 |
Why?
|
Sclerosis | 1 | 2017 | 68 | 0.040 |
Why?
|
Neuronal Tract-Tracers | 1 | 2017 | 1 | 0.040 |
Why?
|
Neuroanatomical Tract-Tracing Techniques | 1 | 2017 | 1 | 0.040 |
Why?
|
Fixatives | 1 | 2017 | 7 | 0.040 |
Why?
|
Tissue Fixation | 1 | 2017 | 10 | 0.040 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2017 | 14 | 0.040 |
Why?
|
Formaldehyde | 1 | 2017 | 14 | 0.040 |
Why?
|
Species Specificity | 1 | 2017 | 70 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2017 | 65 | 0.040 |
Why?
|
Cats | 1 | 2017 | 76 | 0.040 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2017 | 4 | 0.040 |
Why?
|
Central Nervous System | 1 | 2017 | 57 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 17 | 0.040 |
Why?
|
Mental Status Schedule | 2 | 2007 | 113 | 0.040 |
Why?
|
Child | 3 | 2012 | 1346 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2016 | 8 | 0.040 |
Why?
|
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 6 | 0.040 |
Why?
|
Monitoring, Ambulatory | 1 | 2016 | 19 | 0.040 |
Why?
|
Zinc Fingers | 1 | 2016 | 10 | 0.040 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2016 | 18 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2016 | 53 | 0.040 |
Why?
|
Arterioles | 1 | 2016 | 14 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 50 | 0.040 |
Why?
|
Organ Specificity | 1 | 2016 | 47 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 41 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2015 | 16 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2015 | 52 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 432 | 0.030 |
Why?
|
Polysomnography | 1 | 2015 | 92 | 0.030 |
Why?
|
Awareness | 1 | 2015 | 37 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2016 | 219 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2015 | 23 | 0.030 |
Why?
|
Transcription Initiation Site | 1 | 2014 | 3 | 0.030 |
Why?
|
Introns | 1 | 2014 | 15 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2015 | 64 | 0.030 |
Why?
|
Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
Receptors, Kainic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
Forkhead Box Protein O3 | 1 | 2014 | 6 | 0.030 |
Why?
|
Galanin | 1 | 2014 | 4 | 0.030 |
Why?
|
Empathy | 1 | 2014 | 35 | 0.030 |
Why?
|
National Institute on Aging (U.S.) | 1 | 2014 | 18 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2014 | 40 | 0.030 |
Why?
|
Mental Recall | 1 | 2014 | 74 | 0.030 |
Why?
|
Raphe Nuclei | 1 | 2013 | 8 | 0.030 |
Why?
|
Ventral Tegmental Area | 1 | 2013 | 12 | 0.030 |
Why?
|
Medicare Part D | 1 | 2013 | 7 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2016 | 788 | 0.030 |
Why?
|
Chronic Disease | 2 | 2007 | 495 | 0.030 |
Why?
|
ARNTL Transcription Factors | 1 | 2013 | 8 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 58 | 0.030 |
Why?
|
Mutation Rate | 1 | 2012 | 4 | 0.030 |
Why?
|
Motor Neuron Disease | 1 | 1992 | 4 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2012 | 56 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 487 | 0.030 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2012 | 27 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2012 | 19 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2004 | 45 | 0.030 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2012 | 12 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2012 | 10 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2012 | 81 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2012 | 30 | 0.030 |
Why?
|
Muscle Spasticity | 1 | 1992 | 16 | 0.030 |
Why?
|
Electrodes | 1 | 1992 | 16 | 0.030 |
Why?
|
Neural Pathways | 1 | 2012 | 83 | 0.030 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2012 | 31 | 0.030 |
Why?
|
Obesity | 1 | 2015 | 291 | 0.030 |
Why?
|
Psychological Tests | 1 | 2012 | 52 | 0.030 |
Why?
|
Income | 1 | 2012 | 74 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 1992 | 46 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2004 | 193 | 0.030 |
Why?
|
Parenteral Nutrition, Total | 1 | 1991 | 3 | 0.030 |
Why?
|
Up-Regulation | 1 | 2013 | 174 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2004 | 246 | 0.030 |
Why?
|
Monocytes | 1 | 2012 | 116 | 0.030 |
Why?
|
Phlebotomy | 1 | 2011 | 4 | 0.030 |
Why?
|
Parents | 1 | 2012 | 105 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2012 | 143 | 0.030 |
Why?
|
Pentetic Acid | 1 | 1990 | 1 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 1990 | 4 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1990 | 13 | 0.020 |
Why?
|
Housing for the Elderly | 1 | 2010 | 7 | 0.020 |
Why?
|
Anemia | 1 | 2011 | 97 | 0.020 |
Why?
|
Injections | 2 | 2005 | 56 | 0.020 |
Why?
|
Pain Measurement | 1 | 1992 | 462 | 0.020 |
Why?
|
Social Support | 1 | 2011 | 185 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 389 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 1993 | 349 | 0.020 |
Why?
|
Differential Threshold | 1 | 2008 | 3 | 0.020 |
Why?
|
Ultrasonography | 2 | 2005 | 226 | 0.020 |
Why?
|
Functional Laterality | 1 | 1988 | 91 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 33 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2007 | 113 | 0.020 |
Why?
|
Observation | 1 | 2007 | 16 | 0.020 |
Why?
|
Visual Acuity | 1 | 2007 | 42 | 0.020 |
Why?
|
Personality Assessment | 1 | 2006 | 38 | 0.020 |
Why?
|
Fear | 1 | 2006 | 47 | 0.020 |
Why?
|
Syndrome | 1 | 1986 | 82 | 0.020 |
Why?
|
Musculoskeletal Manipulations | 1 | 2005 | 5 | 0.020 |
Why?
|
Education | 1 | 2005 | 39 | 0.020 |
Why?
|
DNA | 1 | 2005 | 125 | 0.020 |
Why?
|
Salivation | 1 | 2005 | 1 | 0.020 |
Why?
|
Parotid Gland | 1 | 2005 | 15 | 0.020 |
Why?
|
West Nile virus | 1 | 2004 | 2 | 0.020 |
Why?
|
Glutamate Decarboxylase | 1 | 2004 | 4 | 0.020 |
Why?
|
Viral Nonstructural Proteins | 1 | 2004 | 9 | 0.020 |
Why?
|
Isoenzymes | 1 | 2004 | 50 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2005 | 227 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 437 | 0.020 |
Why?
|
Autoantibodies | 1 | 2004 | 100 | 0.010 |
Why?
|
Cyclins | 1 | 2000 | 6 | 0.010 |
Why?
|
G1 Phase | 1 | 2000 | 14 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 21 | 0.010 |
Why?
|
Cell Division | 1 | 2000 | 113 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 71 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2000 | 55 | 0.010 |
Why?
|
Biomechanical Phenomena | 1 | 2001 | 668 | 0.010 |
Why?
|
Apoptosis | 1 | 2000 | 251 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2005 | 3478 | 0.010 |
Why?
|
Muscular Atrophy, Spinal | 1 | 1992 | 1 | 0.010 |
Why?
|
Pedigree | 1 | 1992 | 77 | 0.010 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 1992 | 22 | 0.010 |
Why?
|
Kidney Function Tests | 1 | 1991 | 21 | 0.010 |
Why?
|
Urinalysis | 1 | 1991 | 9 | 0.010 |
Why?
|
Blood Chemical Analysis | 1 | 1991 | 13 | 0.010 |
Why?
|
Infant | 1 | 1991 | 531 | 0.010 |
Why?
|
Child, Preschool | 1 | 1991 | 642 | 0.010 |
Why?
|